Strides Pharma Science receives USFDA approval for Theophylline Extended-Release Tablets, 300mg and 450mg
Product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), THEO-DUR®, of Schering Corp
Theophylline Extended-Release Tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases
Theophylline Extended-Release Tablets, 300mg and 450mg, have a combined market size of ~USS 11.5 mn
Products will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India
Strides Pharma Science is a global pharmaceutical company headquartered in Bengaluru, India, and is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR)